SIGA TECHNOLOGIES INC
SIGASIGA Technologies, Inc. is an American pharmaceutical company founded in 1995, based in New York City, which develops and sells pharmaceutical solutions for the antiviral treatment of smallpox, monkeypox, cowpox, and vaccinia complications.
Drugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
SIGA Earnings Report
FQ end 2026-06 | Call: 2026-08-06 15:00:00
How SIGA's past catalysts played out
tecovirimat
Smallpox
TPOXX
Smallpox
Smallpox and Mpox Vaccine
Smallpox
ST-246 400 mg
Orthopoxviral Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
tecovirimat | Phase 3 | Smallpox | - | - |
TPOXX | Phase 3 | Smallpox | - | - |
Smallpox and Mpox Vaccine | Phase 2 | Smallpox | - | - |
ST-246 400 mg | Phase 2 | Orthopoxviral Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in SIGA TECHNOLOGIES INC's drug pipeline?→
CatalystAlert tracks 4 drug candidates in SIGA TECHNOLOGIES INC's (SIGA) pipeline across Phase 3, Phase 2. Its lead program is tecovirimat (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is SIGA TECHNOLOGIES INC's next FDA catalyst?→
SIGA TECHNOLOGIES INC's (SIGA) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SIGA biotech catalysts?→
Add SIGA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow SIGA TECHNOLOGIES INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.